Unknown

Dataset Information

0

Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure.


ABSTRACT: BACKGROUND:Central sleep apnea is associated with poor prognosis and death in patients with heart failure. Adaptive servo-ventilation is a therapy that uses a noninvasive ventilator to treat central sleep apnea by delivering servo-controlled inspiratory pressure support on top of expiratory positive airway pressure. We investigated the effects of adaptive servo-ventilation in patients who had heart failure with reduced ejection fraction and predominantly central sleep apnea. METHODS:We randomly assigned 1325 patients with a left ventricular ejection fraction of 45% or less, an apnea-hypopnea index (AHI) of 15 or more events (occurrences of apnea or hypopnea) per hour, and a predominance of central events to receive guideline-based medical treatment with adaptive servo-ventilation or guideline-based medical treatment alone (control). The primary end point in the time-to-event analysis was the first event of death from any cause, lifesaving cardiovascular intervention (cardiac transplantation, implantation of a ventricular assist device, resuscitation after sudden cardiac arrest, or appropriate lifesaving shock), or unplanned hospitalization for worsening heart failure. RESULTS:In the adaptive servo-ventilation group, the mean AHI at 12 months was 6.6 events per hour. The incidence of the primary end point did not differ significantly between the adaptive servo-ventilation group and the control group (54.1% and 50.8%, respectively; hazard ratio, 1.13; 95% confidence interval [CI], 0.97 to 1.31; P=0.10). All-cause mortality and cardiovascular mortality were significantly higher in the adaptive servo-ventilation group than in the control group (hazard ratio for death from any cause, 1.28; 95% CI, 1.06 to 1.55; P=0.01; and hazard ratio for cardiovascular death, 1.34; 95% CI, 1.09 to 1.65; P=0.006). CONCLUSIONS:Adaptive servo-ventilation had no significant effect on the primary end point in patients who had heart failure with reduced ejection fraction and predominantly central sleep apnea, but all-cause and cardiovascular mortality were both increased with this therapy. (Funded by ResMed and others; SERVE-HF ClinicalTrials.gov number, NCT00733343.).

SUBMITTER: Cowie MR 

PROVIDER: S-EPMC4779593 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure.

Cowie Martin R MR   Woehrle Holger H   Wegscheider Karl K   Angermann Christiane C   d'Ortho Marie-Pia MP   Erdmann Erland E   Levy Patrick P   Simonds Anita K AK   Somers Virend K VK   Zannad Faiez F   Teschler Helmut H  

The New England journal of medicine 20150901 12


<h4>Background</h4>Central sleep apnea is associated with poor prognosis and death in patients with heart failure. Adaptive servo-ventilation is a therapy that uses a noninvasive ventilator to treat central sleep apnea by delivering servo-controlled inspiratory pressure support on top of expiratory positive airway pressure. We investigated the effects of adaptive servo-ventilation in patients who had heart failure with reduced ejection fraction and predominantly central sleep apnea.<h4>Methods</  ...[more]

Similar Datasets

| S-EPMC9909211 | biostudies-literature
| S-EPMC8762030 | biostudies-literature
| S-EPMC8195885 | biostudies-literature
| S-EPMC9252521 | biostudies-literature
| S-EPMC3208847 | biostudies-literature
| S-EPMC7371028 | biostudies-literature
| S-EPMC3482612 | biostudies-literature
| S-EPMC6277244 | biostudies-literature
| S-EPMC4077413 | biostudies-other